Czech VILP Highly Innovative Drug Program (temporary-reimbursement pathway)
A Czech program that allows temporary reimbursement for expensive, innovative drugs that don't meet standard cost-effectiveness criteria, while real-world data is gathered to confirm their value.
At a glance
Use when
Assessing reimbursement for innovative, high-cost drugs with limited initial evidence
Avoid when
Dealing with drugs that have strong existing evidence or low innovation level
Inputs
High-cost innovative drug applications with preliminary evidence of clinical benefit
Outputs
Temporary reimbursement decision with requirement for real-world evidence generation
How it works
The VILP (Very Innovative Medicinal Products) pathway, managed by SUKL in the Czech Republic, provides 2-3 years of temporary reimbursement for high-cost drugs exceeding standard cost-effectiveness thresholds. This conditional access supports evidence generation through real-world data collection to inform long-term reimbursement decisions.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Organisational aspects
- Assumptions
- Real-world evidence collected during the temporary period will clarify long-term effectiveness and value
- Strengths
- Enables patient access to promising therapies; incentivizes innovation; reduces evidence gaps over time
- Limitations
- Risk of funding drugs that later prove not cost-effective; requires robust post-market monitoring
- Also known as
- VILP, Very Innovative Medicinal Products Program
Questions this answers
- › How can innovative but costly drugs gain early reimbursement despite uncertain evidence?
- › What mechanisms support evidence generation post-launch?
- › How does the Czech Republic manage access to high-cost innovative therapies?
- › What criteria define a 'very innovative' drug in the Czech system?
- › How long does temporary reimbursement last under VILP?
- › What happens after the temporary reimbursement period ends?
References & sources
Similar by meaning
- Czech HTA framework for pharmaceutical reimbursement (SUKL cost-effectiveness and budget-impact)
- Czech MCDA approach for orphan-drug decision making
- Swedish Value-Based Pricing reimbursement system (TLV)
- Slovak legally-facilitated performance-based Managed Entry Agreements
- SMC Ultra-Orphan Medicines Pathway
Beta record. Based on the original catalogue summary; primary-source enrichment pending.